# Hematologic Malignancies (HM) Research Program

> **NIH NIH P30** · NORTHWESTERN UNIVERSITY · 2021 · $50,261

## Abstract

ABSTRACT – HEMATOLOGIC MALIGNANCIES
The Hematologic Malignancies (HM) Program of the Lurie Cancer Center (LCC) combines the talents and
expertise of outstanding basic scientists, nationally recognized clinical researchers, and translational
investigators. The goal of the program is to leverage discoveries from member laboratories into clinical
interventions for the treatment of malignant hematologic diseases. This goal is pursued through two program
aims: a) Identify key pathways that regulate hematopoiesis and lymphopoiesis and determine the functional
significance of their alteration in hematologic malignancies, and b) Define molecular therapeutic targets and
evaluate the efficacy of novel agents in clinical trials for hematologic malignancies. Disease specific areas of
focus for program members include acute and chronic myeloid leukemia, myeloproliferative neoplasms (MPNs),
acute and chronic lymphoid leukemia, lymphomas, and multiple myeloma. HM members have made significant
contributions to our understanding of molecular and cellular drivers of hematologic malignancies; specifically, in
the areas of epigenetic modification, cellular signaling and gene expression. Translation of these results to
clinical trials is facilitated by an extensive network of collaborative interactions between laboratory-based faculty
and clinical investigators in the program. During the current funding period, such intra-programmatic interactions
resulted in a number of therapeutic clinical trials that were developed from work in investigator laboratories.
This multidisciplinary inter-departmental program has 32 members from 10 departments in 3 schools. During the
current funding period, program members published 520 papers that were relevant to malignant hematologic
diseases. 131 (25%) of these publications represented intra-programmatic collaborations, 91 (18%) inter-
programmatic collaborations, and 68% involved inter-institutional collaborations. 143 (28%) were high impact
(impact factor >9). Peer reviewed funding for program members totaled $5,190,595 (direct) with $2,117,851
(direct) from the NCI, and $3,072,744 (direct) from other NIH institutes and other sources. Program Leader
Elizabeth Eklund, MD and co-leader Leo Gordon, MD have complementary expertise in the areas of laboratory
investigation, translational research and clinical trials for hematologic malignancies. They work together to foster
collaborative interactions between program members through regularly occurring clinical and research oriented
conferences, retreats and other program activities.!

## Key facts

- **NIH application ID:** 10228205
- **Project number:** 5P30CA060553-27
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Elizabeth Ann Eklund
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $50,261
- **Award type:** 5
- **Project period:** 1997-08-15 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10228205

## Citation

> US National Institutes of Health, RePORTER application 10228205, Hematologic Malignancies (HM) Research Program (5P30CA060553-27). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10228205. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*